|
|
Volumn 3 Suppl 4, Issue , 2003, Pages
|
|
Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CA 15-3 ANTIGEN;
CANCER VACCINE;
CYCLOPHOSPHAMIDE;
GLYCOCONJUGATE;
HEMOCYANIN;
IMMUNOLOGIC FACTOR;
SIALYL TN ANTIGEN KEYHOLE LIMPET HEMOCYANIN CONJUGATE;
SIALYL-TN ANTIGEN-KEYHOLE-LIMPET HEMOCYANIN CONJUGATE;
TUMOR ANTIGEN;
ANIMAL;
BREAST TUMOR;
CLINICAL TRIAL;
FEMALE;
HUMAN;
IMMUNOLOGY;
INTRAVENOUS DRUG ADMINISTRATION;
ORAL DRUG ADMINISTRATION;
REVIEW;
SURVIVAL;
TREATMENT OUTCOME;
ADMINISTRATION, ORAL;
ANIMALS;
ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE;
BREAST NEOPLASMS;
CA-15-3 ANTIGEN;
CANCER VACCINES;
CLINICAL TRIALS;
CYCLOPHOSPHAMIDE;
FEMALE;
GLYCOCONJUGATES;
HEMOCYANIN;
HUMANS;
IMMUNOLOGIC FACTORS;
INFUSIONS, INTRAVENOUS;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 0346364653
PISSN: 15268209
EISSN: None
Source Type: Journal
DOI: 10.3816/cbc.2003.s.002 Document Type: Review |
|
Times cited : (74)
|
|
References (41)
|
